definiens: ) to the License Agreement, as defined below, enteredinto as of the 17 day of March, 2014 ( hereinafter called ) is by and betweenAstraZeneca AB, a Swedish corporation having its principal place of business at Västra Mälarehamnen 9, Södertälje, SE-151 85, Sweden ( ), and Flexion Therapeutics, Inc., a corporation organized under the laws of theState of Delaware and having a principal place of business at 10 Mall Road Suite 301, Burlington Massachusetts01803 ( ) . [COMPANY] and Flexion are hereinafter referred to each as a and collectively as theWHEREAS, [COMPANY] and Flexion Therapeutics entered into that certain license agreement effectiveSeptember 13, 2010 ( ) under which Flexion Therapeutics AG obtained from [COMPANY] andAstraZeneca granted to Flexion Therapeutics AG certain licenses to develop and commercialize the Compounds andLicensed Products